Compare NKTX & AOMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NKTX | AOMR |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.2M | 191.5M |
| IPO Year | 2020 | 2019 |
| Metric | NKTX | AOMR |
|---|---|---|
| Price | $2.25 | $7.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $10.83 | $10.35 |
| AVG Volume (30 Days) | ★ 560.9K | 139.2K |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 17.61% |
| EPS Growth | 11.88 | ★ 53.85 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.70 | $7.11 |
| 52 Week High | $3.72 | $9.48 |
| Indicator | NKTX | AOMR |
|---|---|---|
| Relative Strength Index (RSI) | 31.83 | 33.41 |
| Support Level | $1.96 | $7.11 |
| Resistance Level | $2.50 | $9.24 |
| Average True Range (ATR) | 0.16 | 0.21 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 12.35 | 10.22 |
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in first and second lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation, across interest rate and credit cycles. The company operates in a single operating segment, which is to acquire, invest in, and finance mortgage-related assets.